A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05856500
Collaborator
(none)
152
2
31

Study Details

Study Description

Brief Summary

Cachexia is a common complication of various advanced malignant tumors, which seriously affects the quality of life and survival time of patients. In view of the clinical problem of non-nutritional response in patients with cachexia, the investigators plan to carry out a clinical case-control study on the intervention of creatine combined with curcumin in participants with cachexia. On the whole, the investigators limited the study subjects to upper digestive tract tumors and diagnosed participants with early cachexia. The main purpose of this study is to determine whether the combination of the two can play a positive and stable role in inhibiting the inflammation of cachexia and improving metabolic status, so that basic nutrition can play a role, in order to reduce the level of skeletal muscle consumption, maintain weight, improve quality of life, save medical costs and extend survival time.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: basic nutrition
  • Dietary Supplement: oral supplement of creatine and curcumin
N/A

Detailed Description

This is a prospective open controlled study. The intervention is targeted at participants with early cachexia in upper gastrointestinal tumors.Both control group and intervention group receive basic nutritional support. On the basis of this, the intervention group will be given creatine and curcumin orally.The purpose is to investigate whether creatine combined with curcumin can improve the inflammatory and the nutritional state, correct the disorder of nutrient metabolism and improve the prognosis of participants.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
152 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Prospective Open Controlled Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Aug 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: basic nutrition

basic nutrition treatment, energy 30-35 kcal/kg, protein 1.0-2.0 g/kg, total nutrition and/or whey protein oral nutrition supplement or tube feeding enteral nutrition supplement if diet deficiency;

Dietary Supplement: basic nutrition
An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.

Experimental: oral supplement of creatine and curcumin

On the basis of basic nutrition in group A, creatine 5g/d and curcumin 4g/d are orally added, and the intervention time is 1 month.

Dietary Supplement: oral supplement of creatine and curcumin
Creatine and curcumin are orally added other than basic nutrition treatment.

Outcome Measures

Primary Outcome Measures

  1. L3 skeletal muscle index(c㎡/㎡) [0-month]

    CT scans L3 cross-sectional skeletal muscle area/height²

  2. L3 skeletal muscle index(c㎡/㎡) [1-month]

    CT scans L3 cross-sectional skeletal muscle area/height²

  3. Appendicular skeletal muscle mass index(kg/㎡) [0-month]

    Appendicular skeletal muscle mass(ASM)is measured by bioelectrical impedance analysis(BIA), the ASM index (ASM/height²)is calculated.

  4. Appendicular skeletal muscle mass index(kg/㎡) [1-month]

    Appendicular skeletal muscle mass(ASM)is measured by bioelectrical impedance analysis(BIA), the ASM index (ASM/height²)is calculated.

Secondary Outcome Measures

  1. Pre-albumin concentration(mg/L) [0-month]

    Serological pre-albumin concentration

  2. Pre-albumin concentration(mg/L) [1-month]

    Serological pre-albumin concentration

  3. Albumin concentration(g/L) [0-month]

    Serological albumin concentration

  4. Albumin concentration(g/L) [1-month]

    Serological albumin concentration

  5. Body Mass Index(kg/㎡) [0-month]

    body weight/height²

  6. Body Mass Index(kg/㎡) [1-month]

    body weight/height²

  7. Nutrition intake level(%) [0-month]

    Investigate the ratio of actual energy and protein intake levels to target intake levels

  8. Nutrition intake level(%) [1-month]

    Investigate the ratio of actual energy and protein intake levels to target intake levels

  9. PG-SGA score [0-month]

    Scored Patient-Generated Subjective Global Assessment(PG-SGA):(0-1,stage A;2-8,stage B;≥9,stageC)

  10. PG-SGA score [1-month]

    Scored Patient-Generated Subjective Global Assessment(PG-SGA):(0-1,stage A;2-8,stage B;≥9,stageC)

  11. Functional Assessment of Anorexia/Cachexia Therapy(FAACT) [0-month]

    Anorexia/Cachexia Sub-scale-12:score 0~24,Anorexia/Cachexia

  12. Functional Assessment of Anorexia/Cachexia Therapy(FAACT) [1-month]

    Anorexia/Cachexia Sub-scale-12:score 0~24,Anorexia/Cachexia

  13. Survival rate(%) [1-month]

    (Number of surviving cases after 1 month of follow-up)/(number of cases at the beginning of follow-up) ×100%

  14. Survival rate(%) [3-month]

    (Number of surviving cases after 3 month of follow-up)/(number of cases at the beginning of follow-up) ×100%

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of advanced tumors of the upper digestive tract with untreatable or postoperative recurrence of esophageal and gastric cancer III-IV

  • Meet the diagnostic criteria of early cachexia (anorexia and metabolic changes, involuntary body mass reduction ≤5% within 6 months)

  • Radiotherapy, chemotherapy or immunotherapy in our hospital

  • Understand and fill in a variety of rating scales

  • Informed consent, voluntary participation in this study

Exclusion Criteria:
  • Neoadjuvant chemotherapy patients

  • Intestinal obstruction or gastrointestinal bleeding

  • Severe heart, lung and renal insufficiency

  • Coagulopathy

  • Clinical diagnosis with diabetes and other metabolic diseases

  • The expected survival time is less than 1 month

  • With cognitive dysfunction or poor coordination

  • Allergy to creatine or curcumin

  • With a history of drug abuse

  • Doctors or researchers deem unsuitable for study participation

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
ClinicalTrials.gov Identifier:
NCT05856500
Other Study ID Numbers:
  • 2022-223-02
First Posted:
May 12, 2023
Last Update Posted:
May 18, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2023